Related Experiment Videos
Green light phototherapy in newborn infants with ABO hemolytic disease
H Ayyash1, E Hadjigeorgiou, J Sofatzis
1Second Department of Pediatrics, University of Athens Medical School, Leto, Maternity Hospital, Greece.
Insights
Green light phototherapy is as effective as blue light for treating infant jaundice from ABO incompatibility. This finding, along with blue light
Area of Science:
- Neonatal Medicine
- Phototherapy Research
- Biomedical Engineering
Background:
- Neonatal jaundice, particularly due to ABO incompatibility, is a common clinical challenge.
- Phototherapy is a standard treatment, but light spectrum efficacy requires further investigation.
- Concerns exist regarding potential genotoxicity of blue light.
Purpose of the Study:
- To compare the efficacy of green light phototherapy versus blue light phototherapy.
- To evaluate treatment effectiveness based on serum bilirubin photodegradation rates.
- To assess the safety and applicability of green light phototherapy for neonatal hyperbilirubinemia.
Main Methods:
- Full-term infants with ABO incompatibility jaundice were enrolled.
- Treatment groups received either green light or blue light phototherapy.
- Efficacy was measured by serum bilirubin photodegradation rates (actual and quantum efficiency).
Main Results:
- No statistically significant difference in bilirubin photodegradation rates was observed between green and blue light groups.
- Treatment durations were comparable: 84.6 ± 14.1 hours (green) vs. 81.5 ± 14.2 hours (blue).
- Calculated actual and quantum efficiencies showed no significant divergence.
Conclusions:
- Green light phototherapy demonstrates comparable efficacy to blue light for treating neonatal jaundice from ABO incompatibility.
- The established safety profile of green light, avoiding potential blue light genotoxicity, supports its use.
- Green light phototherapy is a viable and potentially safer alternative for this condition.
Abstract:
The efficacy of fluorescent green light phototherapy was compared with that of blue light phototherapy in the treatment of full-term infants with hemolytic disease and jaundice caused by ABO incompatibility. The efficacy of the treatment was expressed as actual (milligrams per hour) and quantum (milligrams per hour per square centimeter per megawatt) efficiency, taking into account the differential emission of energy from the green versus the blue fluorescent tubes. No statistically significant difference in the rate of serum bilirubin photodegradation was found between the two groups after treatment for 84.6 +/- 14.1 hours versus 81.5 +/- 14.2 hours with the green and the blue phototherapy, respectively. These results, coupled with the known effects of the blue light on the genetic apparatus of mammalian cells, support the application of the green light phototherapy for the treatment of neonatal hyperbilirubinemia caused by ABO incompatibility.